e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 46

Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease

Florence T.H. Wu; Ping Xu; Annabelle Chow; Shan Man; Janna Krüger; Kabir A. Khan; Marta Pàez‐Ribes; Elizabeth Pham · 2018 · British Journal of Cancer

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

There are phase 3 clinical trials underway evaluating anti-PD-L1 antibodies as adjuvant (postoperative) monotherapies for resectable renal cell carcinoma (RCC) and triple-negative breast cancer (TNBC); in combination with antiangiogenic VEGF/VEGFR2 inhibitors (e.g., bevacizumab and sunitinib) for metastatic RCC; and in combination with chemotherapeutics as neoadjuvant (preoperative) therapies for resectable TNBC. This study investigated these and similar clinically relevant drug combinations in highly translational preclinical models of micro- and macro-metastatic disease that spontaneously de

Abstract by Florence T.H. Wu; Ping Xu; Annabelle Chow; Shan Man; Janna Krüger; Kabir A. Khan; Marta Pàez‐Ribes; Elizabeth Pham, British Journal of Cancer (2018) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1038/s41416-018-0297-1